Status: Not yet recruiting
PPI Dosing Per CYP2C19 Genotype
This study is being done to determine if the dosing of proton pump inhibitor (PPI) medication based on CYP2C19 genotype-derived phenotype leads to improved healing of erosive esophagitis compared to conventional PPI medication dosing.
Participants needed: 200
Trial details
Phase: Phase 4Age: 18-90Biological sex: AllType: InterventionalSponsor: University of FloridaUpdated: Sep 28, 2026
Eligibility criteria
age ≥ 18 years [+2]
age <18 years [+2]